Drug development – Page 16

ADME liabilities identified late during early discovery – impact on IND success probability

Exploring Late Identification of ADME Liabilities in Early Discovery and its Impact on IND Success In the highly regulated field of pharmaceutical development, late identification of Absorption, Distribution, Metabolism, and…

ADME liabilities identified late before IND-enabling studies – data package strengthening approach

Addressing Late-Identified ADME Liabilities Before IND-Enabling Studies The identification of Absorption, Distribution, Metabolism, and Excretion (ADME) liabilities at an advanced stage in drug development can lead to significant regulatory challenges…

Off-target toxicity signals before IND-enabling studies – risk mitigation strategy

Identifying and Mitigating Off-Target Toxicity Signals Prior to IND-Enabling Studies In the complex landscape of pharmaceutical development, identifying off-target toxicity signals before initiating Investigational New Drug (IND)-enabling studies is critical…

Reproducibility issues in screening data before IND-enabling studies – decision framework regulators expect

Addressing Reproducibility Issues in Screening Data Prior to IND-Enabling Studies: A Decision Framework for Regulatory Compliance Reproducibility issues in screening data can significantly impact drug discovery and the transition to…

Off-target toxicity signals before IND-enabling studies – how to avoid late-stage attrition

Identifying Off-target Toxicity Signals Prior to IND-enabling Studies: Strategies for Mitigation In the competitive landscape of drug development, late-stage attrition attributable to off-target toxicity presents a significant hurdle. This article…

Reproducibility issues in screening data before IND-enabling studies – data package strengthening approach

Addressing Reproducibility Issues in Screening Data Prior to IND-Enabling Studies Reproducibility issues in screening data can pose significant risks during the drug discovery process, leading to delayed timelines and heightened…

Reproducibility issues in screening data during regulatory interaction preparation – risk mitigation strategy

Addressing Reproducibility Challenges in Screening Data Preparation for Regulatory Interactions In the realm of pharmaceutical research and development, reproducibility issues can severely impact the preparation for regulatory interactions, particularly concerning…

Reproducibility issues in screening data during early discovery – decision framework regulators expect

Addressing Reproducibility Issues in Screening Data During Early Discovery: A Structured Approach In the intricate world of drug discovery, reproducibility issues in screening data can derail even the most promising…

Reproducibility issues in screening data during regulatory interaction preparation – decision framework regulators expect

“`html Framework for Addressing Reproducibility Issues in Screening Data During Regulatory Interactions In the context of drug discovery and preclinical studies, reproducibility issues in screening data can significantly complicate regulatory…

Reproducibility issues in screening data during regulatory interaction preparation – impact on IND success probability

“`html Understanding and Addressing Reproducibility Issues in Screening Data for Regulatory Navigation In the realm of drug discovery, reproducibility issues in screening data can significantly hamper the success of Investigational…

Target validation uncertainty during regulatory interaction preparation – how to avoid late-stage attrition

Navigating Target Validation Uncertainty During Regulatory Interaction Preparation to Mitigate Late-Stage Attrition In the pharmaceutical industry, one of the most critical challenges faced during drug discovery is target validation uncertainty.…

Poor hit-to-lead progression during translational assessment – impact on IND success probability

Understanding Poor Hit-to-Lead Progression During Translational Assessment and Its Implications for IND Success The pharmaceutical industry faces numerous challenges during the drug development process, particularly in the translational assessment phase.…